Search Within

Dmitriy Zamarin

  1. "2022"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (19)
  3. Editorial (1)
Groups
  1. Department of Medicine (40)
  2. GDMT, Medicine (40)
  3. Gynecologic Medicine Service (40)
  4. Gynecology Disease Management Team (40)
  5. Solid Tumor Oncology Division (40)
  6. Sloan Kettering Institute Postdocs (22)

More Groups

People
  1. Britta Weigelt (16)
  2. Carol Aghajanian (13)
  3. Claire Friedman (12)
  4. Nadeem Abu-Rustum (11)
  5. Roisin O'Cearbhaill (8)
  6. Sohrab Shah (8)

More People

Years
  1. 2022 (40)
Publications
  1. Cancer Research (10)
  2. Gynecologic Oncology (6)
  3. Journal of Clinical Oncology (5)
  4. International Journal of Gynecological Cancer (3)
  5. Nature (3)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (12)
  2. American Society of Clinical Oncology (7)
  3. Elsevier Inc. (6)
  4. Nature Publishing Group (4)
  5. Lippincott Williams & Wilkins (3)
  6. Biomed Central Ltd (2)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic instability as a determinant of immune escape in ovarian cancer
    Meeting Abstract

    Vazquez-Garcia, I.; Uhlitz, F.; Ceglia, N.; Lim, J.; Wu, M.; Mohibullah, N.; Niyazov, J.; Ruiz, A. E.; Soslow, R.; Ellenson, L.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Exploiting SMARCA2 dependency for targeted therapy in SMARCA4-deficient ovarian cancers
    Meeting Abstract

    Brodeur, M.; Dopeso, H.; Green, H.; Ito, K.; Hulse, M.; Brown, J.; Weigelt, B.; Zamarin, D.
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Endogenous retrotransposable elements induction in SMARCA4-deficient ovarian cancer is associated with immunomodulatory changes in the tumor microenvironment
    Meeting Abstract

    Brodeur, M. N.; Sun, S.; Zhu, Y.; Greenbaum, B.; Weigelt, B.; Zamarin, D.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • What matters most in FIGO IIIA endometrial cancer: Involvement of serosa, adnexa, or both?
    Meeting Abstract

    Rios-Doria, E.; Abu-Rustum, N.; Glaser, G.; McGree, M.; Eriksson, A. G. Z.; Pham, M.; Soliman, P.; Ataseven, B.; Alektiar, K.; Zamarin, D.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Molecular classification of endometrial carcinomas: A single-institution review
    Meeting Abstract

    Rios-Doria, E.; Abu-Rustum, N.; Leitao, M.; Alektiar, K.; Makker, V.; Liu, Y.; Zamarin, D.; Friedman, C.; Aghajanian, C.; Ellenson, L.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Safety and immunogenicity of anti PD-L1 (atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: An NRG oncology trial
    Meeting Abstract

    Mayadev, J.; Zamarin, D.; Deng, W.; Lankes, H.; Pesci, G.; Park, K.; Banbury, B.; Sherry, N.; Ghamande, S.; Holman, L.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Single-cell genomic variation induced by mutational processes in cancer
    Journal Article

    Funnell, T.; O’Flanagan, C. H.; Williams, M. J.; McPherson, A.; McKinney, S.; Kabeer, F.; Lee, H.; Salehi, S.; Vázquez-García, I.; Shi, H.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • Ovarian cancer mutational processes drive site-specific immune evasion
    Journal Article

    Vázquez-García, I.; Uhlitz, F.; Ceglia, N.; Lim, J. L. P.; Wu, M.; Mohibullah, N.; Niyazov, J.; Ruiz, A. E. B.; Boehm, K. M.; Bojilova, V.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers
    Journal Article

    Ehmann, S.; Sassine, D.; Straubhar, A. M.; Praiss, A. M.; Aghajanian, C.; Alektiar, K. M.; Broach, V.; Cadoo, K. A.; Jewell, E. L.; Boroujeni, A. M.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results
    Meeting Abstract

    Zamarin, D.; Odunsi, K.; Zsiros, E.; Slomovitz, B. M.; Pimentel, A.; Duska, L. R.; Reilley, M.; Nemunaitis, J. J.; Hamouda, D. M.; Patel, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save